Fertility preservation in BRCA-mutated women: when and how? - Archive ouverte HAL Access content directly
Journal Articles Future Oncology Year : 2018

Fertility preservation in BRCA-mutated women: when and how?

(1) , , , , ,
J Raad
  • Function : Author
M Comtet
  • Function : Author
C Vinolas
  • Function : Author
I Cedrin-Durnerin
  • Function : Author
C Sonigo
  • Function : Author


BRCA 1 and 2 genes play a critical role in the safeguarding of DNA integrity. It is now well established that BRCA1 and BRCA2-mutated women are at increased risk of breast and ovarian cancers. However, several lines of evidence indicate that this genetic status may also be associated with ovarian dysfunction, in particular a reduced ovarian reserve. Considering the gonadal toxicity of cancer treatments and the recommendation of prophylactic bilateral salpingo-oophorectomy around 40 years, young BRCA mutation carriers are confronted with difficult family planning decisions. Recent development in fertility preservation offers new possibilities for these women, not only before a potential cancer treatment, but also in healthy carriers. If the pregnancy seems to be safe in this population, oocyte vitrification following ovarian stimulation might help BRCA-mutated patients to conceive after cancer treatment or to undergo prenatal genetic diagnosis in order to avoid the risk of transmitting the genetic abnormality to their offspring. The present article aims to extensively discuss the fertility issues related to BRCA gene mutations and the questions raised by the possibility of fertility in this population.
Not file

Dates and versions

hal-03105440 , version 1 (11-01-2021)



M Grynberg, J Raad, M Comtet, C Vinolas, I Cedrin-Durnerin, et al.. Fertility preservation in BRCA-mutated women: when and how?. Future Oncology, 2018, 14 (5), ⟨10.2217/fon-2017-0415⟩. ⟨hal-03105440⟩
16 View
0 Download



Gmail Facebook Twitter LinkedIn More